(Reuters) — Merck & Co is nearing a $1.3 billion cash deal to buy ophthalmology biotechnology company Eyebiotech in an agreement that could see an additional $1.7 billion in milestone payments ...

Merck has struck a $1.3 billion deal to buy Eyebiotech, a move that would push ... which goes by the name EyeBio.

(Reuters) -Merck on Wednesday agreed to buy ... cash and another $1.7 billion in future milestone-based payments for EyeBio, and will gain access to its retinal disease drug Restoret as part of ...

Investing.com-- Merck&Company Inc (NYSE:MRK) is close to entering a $1.3 billion deal to buy Eyebiotech ... is expected to pay $1.3 billion in cash for the ophthalmology firm, and could pay ...

What Happened: The deal, which could be announced as early as Wednesday, will see Merck pay $1.3 billion in cash upfront to acquire EyeBio, a privately held biotech firm. Merck could also make ...

FILE PHOTO: Signage is seen at the Merck & Co. headquarters in Kenilworth ... Bill Gates Says He Donated $100 Billion Of His Wealth To Charitable Causes, But He 'Didn't Order Less Hamburgers ...

(Reuters) — Merck & Co is nearing a $1.3 billion cash deal to buy ophthalmology biotechnology company Eyebiotech in an agreement that could see an additional $1.7 billion in milestone payments, the ...

London: Merck & Co is nearing a $1.3 billion cash deal to buy ophthalmology biotechnology company Eyebiotech in an agreement that could see an additional $1.7 billion in milestone payments ...